CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Published: 17 Jun 2020
Views: 2948
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC.
Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.
This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.
Related Videos
IMpower133: Exploratory analysis of maintenance therapy in patients with exten...
Prof Martin Reck and Dr Antonio Passaro
1 Apr 2021
Promise of personalised medicine for patients with prostate cancer
Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt ...
26 Feb 2021
Latest in NSCLC from WCLC 2020
Prof Solange Peters, Dr Melissa Johnson, Prof Heather Wakelee and Dr Jay Lee
24 Feb 2021
The role of immune checkpoint inhibitors in NSCLC
Dr Maurice Pérol, Centre Léon Bérard, Lyon, France
27 Jan 2021
Latest data for managing ALK NSCLC patients
Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea
11 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-sma...
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
Why the ADAURA study is a big step forward for NSCLC
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
17 Jul 2020
